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Abstract
Breast cancer preferentially metastasizes to lung, lymph node, liver, bone, and brain. However, it is unclear whether properties of
cancer cells, properties of organmicroenvironments, or a combination of both is responsible for this observed organ tropism.We
hypothesized that breast cancer cells exhibit distinctive migration/growth patterns in organ microenvironments that mirror
common clinical sites of breast cancer metastasis and that receptor-ligand interactions between breast cancer cells and soluble
organ-derived factorsmediate this behavior. Using an ex vivomodel system composed of organ-conditionedmedia (CM), human
breast cancer cells (MDA-MB-231,MDA-MB-468, SUM149, and SUM159) displayed cell line–specific and organ-specific patterns
of migration/proliferation that corresponded to their in vivometastatic behavior. Notably, exposure to lung-CM increased migra-
tion of all cell lines and increased proliferation in two of four lines (P < .05). Several cluster of differentiation (CD) 44 ligands
including osteopontin (OPN) and L-selectin (SELL) were identified in lung-CM by protein arrays. Immunodepletion of SELL
decreased migration of MDA-MB-231 cells, whereas depletion of OPN decreased both migration and proliferation. Pretreatment
of cells with a CD44-blocking antibody abrogated migration effects (P < .05). “Stemlike” breast cancer cells with high aldehyde
dehydrogenase andCD44 (ALDHhiCD44+) responded in a distinct chemotacticmanner toward organ-CM,preferentiallymigrating
toward lung-CM through CD44 receptor-ligand interactions (P < .05). In contrast, organ-specific changes in migration were not
observed for ALDHlowCD44− cells. Our data suggest that interactions between CD44+ breast cancer cells and soluble factors
present in the lung microenvironment may play an important role in determining organotropic metastatic behavior.
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Introduction
Breast cancer remains a leading cause of morbidity and mortality in
women [1], mainly due to the propensity of primary breast tumors
to metastasize to distant sites and the failure of most therapies in the
metastatic setting. Further insight into the biology of metastasis is
therefore essential to gain a greater understanding of this process and
to develop better cancer therapies.
Metastasis is a complex process, and tumor cells must successfully
negotiate a series of sequential steps to establish clinically relevant
macrometastases. These steps include dissemination from the primary
tumor through blood or lymphatic systems, survival within the cir-
culation, extravasation into secondary sites, initiation of growth into
micrometastases, and maintenance of growth as vascularized macro-
metastases [2]. Clinical observations indicate that many cancers show
an organ-specific pattern of metastasis, termed organ tropism, and it is
well established that breast cancer favors metastasis to the lung, liver,
bone, lymph node (LN), and brain [2–4]. In the 1920s, James Ewing
first proposed that blood flow patterns alone were sufficient to account
for both physical delivery of tumor cells to secondary organs and for
patterns of organ-specific metastasis [5]. However, several theories have
challenged this idea by proposing that there are additional, molecular-
level mechanisms that explain why and how cancer cells can travel to
and grow in “favorite” metastatic sites. Among these is Paget’s seminal
“seed and soil” hypothesis, first proposed in 1889 [6]. This predicts that
a cancer cell (“seed”) can survive and proliferate only in secondary sites
(“soil”) that produce appropriate molecular factors. A meta-analysis of
published autopsy data [7] demonstrated that, in some cases, metastases
detected at autopsy were in proportion to blood flow from the primary
tumor to the secondary organ. However, in many cases, more or fewer
metastases than would be expected by blood flow alone were detected,
indicating that the microenvironment is likely very important for
metastatic dissemination and growth.
For the past several years, elegant work by Joan Massagué and
colleagues has focused on defining specific genes that mediate organ-
specific metastasis in breast cancer [4,8–10]. Using in vivo selection
and genetic analysis of the MDA-MB-231 human breast cancer cell
line, this group demonstrated that particular genes can mediate exper-
imental breast cancer metastasis in an organ-specific manner to lung
[10], bone [9], and brain [8] and validated that these genes reflect
organ-specific metastatic disease in patients with breast cancer. Al-
though these studies contribute valuable knowledge regarding the
contribution of the cancer cell (“seed”) to organ tropism of breast
cancer, the factors contributed by the metastatic microenvironment
(“soil”) still remain poorly understood. In addition, these studies do
not take into account the concepts of tumor cell heterogeneity and
the cancer stem cell hypothesis.
Despite the deadly nature of metastasis, it is an inherently inefficient
process [2,11]. This suggests that only a small subset of cells can
successfully navigate the metastatic cascade. We believe that these
metastasis-initiating cells may in fact be cells with “stemlike” properties
[12]. In breast cancer, tumor-initiating cells have been isolated from
primary tumors and pleural effusions on the basis of a cluster of differ-
entiation (CD) 44-positive–CD24-negative (CD44+CD24−) pheno-
type [13] and/or high aldehyde dehydrogenase (ALDH) activity [14].
Our group and others have demonstrated that breast cancer cells with an
ALDHhiCD44+ phenotype show enhanced metastatic behavior in vitro
and in vivo compared to their ALDHlowCD44− counterparts [15–17].
However, the role of such cells in mediating organ-specific metastasis
has not been investigated.
In the current study, we hypothesized that breast cancer cells exhibit
distinctive growth and migration patterns in organ microenvironments
that mirror common clinical sites of breast cancer metastasis and that
receptor-ligand interactions between breast cancer cells and specific
soluble organ-derived factors can mediate this behavior. We first de-
veloped and validated a comprehensive ex vivo model system for inves-
tigating the influence of organ-specific soluble factors on metastatic
behavior of human breast cancer cells. Our results indicate that human
breast cancer cells with varying genetic backgrounds exhibit differ-
ential migration and growth patterns toward specific organ conditions.
Notably, these patterns reflect the known metastatic dissemination
patterns of these cell lines in vivo and highlight the lung as an im-
portant source of soluble factors that mediate metastatic behavior.
Furthermore, our results suggest for the first time that interactions
between subpopulations of CD44-expressing breast cancer cells
(including ALDHhiCD44+ cells) and soluble ligands present in the
lung microenvironment may play an important role in determining
organotropic metastatic behavior.
Materials and Methods
Cell Culture and Reagents
MDA-MB-231 cells [18] were obtained from American Type
Culture Collection (Manassas, VA) and maintained in Dulbecco’s
modified Eagle’s medium (DMEM)/F12 + 10% FBS. SUM159 and
SUM149 cells [19] were obtained from Asterand Inc (Detroit, MI)
and maintained in HAMS:F12 + 5% FBS + 5 μg/ml insulin + 1 μg/ml
hydrocortisone + 10 mM Hepes. MDA-MB-468 cells were obtained
from Dr Janet Price (MD Anderson Cancer Center, Houston, TX
[20]) and maintained in α minimum essential medium + 10% FBS.
Cell lines were authenticated through third-party testing (CellCheck;
IDEXX RADIL, Columbia, MO) in January 2012. All Media/supple-
ments were from Invitrogen (Carlsbad, CA); FBS was from Sigma-
Aldrich (St Louis, MO).
Organ-Conditioned Media
Healthy female nude mice (Hsd:Athymic Nude-Foxn1nu; Harlan
Sprague-Dawley, Indianapolis, IN) were maintained as per the
Canadian Council of Animal Care under a protocol approved by the
Western University Animal Use Subcommittee (No. 2009-064). Mice
(6-12 weeks old) were euthanized, and individual organs (lung, liver,
and brain), femurs, and axillary/brachial/inguinal LNs were aseptically
removed, washed, and cut into ∼1-mm3 fragments. Liver-conditioned
media (CM) were isolated in the presence of 1X Halt protease inhibitor
(aprotinin, bestatin, E-64, leupeptin, NaF, Na3VO4, Na4P2O7,
and β-glycerophosphate) (Pierce, Nepean, Ontario). Lung, liver, and
brain tissues were weight normalized by resuspending in 4:1 media
to tissue (vol/wt) ratio in DMEM/F12 + 1XMITO+ (BD Biosciences,
Mississauga, Ontario) + penicillin (50 U/ml)/streptomycin (50 μg/ml)
(pen/strep; Invitrogen). Organs were cultured for 24 hours before
collecting CM for storage at −20°C.
Due to the smaller cellular content of LN and bone marrow (BM)
relative to other organs, a different approach was taken to generate CM
from these tissues. LNs were mechanically dissociated, washed, and
plated at a density of 5 × 106 cells per well in six-well dishes in Roswell
Park Memorial Institute Medium 1640 + 10% FBS + pen/strep + 5 ×
10−5 M β-mercaptoethanol (BioShop, Burlington, Ontario) as previ-
ously described [21]. BM was collected by flushing femur cavities as
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previously described [22]. Aspirates were dissociated by pipetting and
washed, and ∼1 × 107 cells were plated in T75 flasks in DMEM +
10% FBS + pen/strep. Resulting adherent LNSCs or BM stromal cells
(BMSCs) were passaged two to three times, washed, and exposed
to DMEM/F12 + MITO+ + pen/strep. CM were collected after
72 hours and stored at −20°C. To account for mouse-to-mouse
variability, organ-CM from multiple mice were pooled before use in
functional experiments.
Migration Assays
Transwells (6.5 mm, 8-μm pore size; Becton Dickinson, Franklin
Lakes, NJ) were coated with 6 μg of gelatin per well as previously
described [16]. Organ-CM [weight normalized to 0.0156 g of tissue
per milliliter of media; determined by dose-response experiments
(Figure W1)], basal media (DMEM/F12 + MITO+), or positive con-
trol media (basal media + 10% FBS) were placed in the bottom portion
of 24-well dishes (n = 3 wells per condition). Human breast cancer cells
(5 × 104 cells per well) were plated on top of transwells. In experiments
involving functional blocking of CD44 or ALDH, cells were pre-
incubated at room temperature (RT) for 30 minutes in the presence
or absence of a broad-spectrum rat anti-human CD44 antibody
(10 μg/ml; clone A020; Calbiochem, Mississauga, Ontario) or 100 μM
diethylaminobenzaldehyde (DEAB) as previously described [17,23].
After 24 hours, transwells were removed, fixed, and stained with
hematoxylin. Nonmigrated cells on the inner surface of transwells were
removed. Five high-powered fields (HPFs) were counted for each
transwell, and mean numbers of migrated cells were calculated using
ImageJ software [National Institutes of Health (NIH), Bethesda, MD].
Results are expressed as fold increase from negative control (basal media)
(N = 3).
Bromodeoxyuridine Assays
Human breast cancer cells (1.5 × 104 per well) were plated onto
eight-well chamber slides (Lab-Tek; Thermo Fisher Scientific,Waltham,
MA) and allowed to adhere for 24 hours (n = 3 wells per condition)
before synchronizing cells into G0 in serum-free DMEM/F12 for
72 hours. In experiments involving CD44 blocking, cells were pre-
treated as described above. Media were changed to organ-CM [weight
normalized to 0.0624 g of tissue per milliliter of media; determined by
dose-response experiments (Figure W2)], basal media, or positive con-
trol media for 24 hours. Cells were pulsed with bromodeoxyuridine
(BrdU) (5 μl/ml; Amersham Cell Proliferation Labeling Reagent; GE
Healthcare, Piscataway, NJ) for 30 minutes, washed, fixed, permeabi-
lized, and denatured. Slides were stained with Anti-BrdU (1:75; BD
Biosciences) for 2 to 3 days in a humid slide chamber. Secondary anti-
body [1:100; fluorescein isothiocyanate (FITC) anti-mouse IgG; Vector
Laboratories, Burlington, Ontario] was added for 1 hour at RT. Slides
were mounted with ProLong Gold with 4′,6-diamidino-2-phenylindole
(DAPI) (Invitrogen) and allowed to cure for 24 hours in the dark at
RT. Images (five HPFs per well) were taken, and nuclei were enu-
merated using ImageJ. Results are normalized to negative control (basal
media) and expressed as a percentage of total nuclei that were BrdU+
(N = 3).
Protein Arrays
To identify soluble factors present within lung-CM, RayBio AAM-
BLM-1 label-based mouse antibody arrays were used to simultaneously
assess expression of 308 soluble murine target proteins (RayBiotech Inc,
Norcross, GA). Postdialysis protein concentration of lung-CM or basal
media (N = 3 per condition) was determined using the DC pro-
tein assay (Bio-Rad Laboratories, Mississauga, Ontario), and 40 μl of
internal array control was spiked into 100 μg of total protein, labeled,
and incubated with protein arrays as per manufacturer’s instructions.
Results were visualized using chemiluminescence and film exposure
(CL-XPosure Film; Pierce).
Densitometric analysis was conducted using ImageJ with the
MicroArray Profile Macro (OptiNav Inc, Bellevue, WA), and results
(N = 3 per media condition) were analyzed using the RayBiotech anal-
ysis tool for AAM-BLM-1. Seventy confirmed protein hits were iden-
tified as having values >1 after background subtraction and validation
across three replicates. Due to differences in antibody affinities for tar-
get antigens, quantitative comparison between different proteins was
not feasible using this platform. The resulting protein list was cross-
referenced with the Ensembl gene database (European Bioinformatics
Institute andWellcomeTrust Sanger Institute,Hinxton,UnitedKingdom;
www.ensembl.org), and gene symbols were queried using Ingenuity
Pathway Analysis (Ingenuity Systems, Redwood City, CA).
Immunodepletion
Target proteins were immunodepleted from lung-CM using anti-
bodies against mouse L-selectin (SELL) (2 μg/ml) or osteopontin
(OPN) (10 μg/ml) (R&D Systems, Burlington, Ontario). Antibodies
were incubated for 20 minutes at RT with Dynabeads Protein G
(Invitrogen) and washed. Bead-antibody complexes were incubated
with lung-CM or basal media (N = 3 per condition) for 30 minutes
at RT. Resulting bead-antibody-antigen complexes were removed using
a DynaMag-2 magnet (Invitrogen), and depleted media were assessed
by Quantikine ELISA kits specific for mouse SELL or OPN (R&D
Systems). Negative controls included media exposed to beads only
(no antibody) or beads + nonspecific IgG antibody.
In Vivo Metastasis Assays
Procedures were conducted in accordance with the recommenda-
tions of Canadian Council of Animal Care, under an approved protocol
(No. 2009-064). Using established models of experimental metastasis,
1 × 106 MDA-MB-231 cells/100 μl sterile Hank’s buffered salt solu-
tion were injected into the lateral tail vein of 7- to 8-week-old female
nude mice (n = 5) as described previously [16]. Lung metastases were
allowed to develop for 8 weeks. Lung tissues collected at necropsy were
formalin fixed, paraffin embedded, serially sectioned (4 μm), stained
with hematoxylin and eosin, and evaluated by microscopy to identify
regions of metastatic involvement. Alternatively, embeddedmouse lung
tissue was deparaffinized, rehydrated, and immersed in sodium citrate
buffer at 100°C for 20 minutes. Slides were blocked by BLOXALL
Endogenous Peroxidase and Alkaline Phosphatase (AP) Blocking Solu-
tion (Vector Laboratories) for 10 minutes at RT and stained by Polink
DS-MR-Hu A2 kit (GBI Labs, Burlington, Ontario) according to
the manufacturer’s instructions. Primary antibodies included rabbit
anti-mouse OPN (1:500; American Research Products, Inc, Waltham,
MA), rabbit anti-mouse SELL (1:500; Bioss, Burlington, Ontario),
and/or mouse anti-human CD44 (1:1000; Abcam, Cambridge, MA)
for 1 hour, followed by incubation with 1:1 HRP-polymer anti-rabbit
IgG and AP-polymer anti-mouse IgG for 30 minutes. Color was devel-
oped using DAB (brown) and AP-Red (Thermo Fisher Scientific).
Slides were counterstained with hematoxylin, mounted, and imaged
using an Image ScanScope (Aperio, Vista, CA).
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Fluorescence-Activated Cell Sorting
Cell subpopulations (ALDHhiCD44+CD24− and ALDHlow-
CD44low/−CD24+) were isolated from the MDA-MB-231 cell line as
described previously [16,17] and in the Supplemental Materials and
Methods section. FACS-isolated cells were used immediately for
in vitro migration assays.
Data Analysis
In vitro experiments were performed a minimum of three times with
at least three technical replicates included within each experiment.
In vivo studies were carried out using multiple mice (N = 5-20 per
experiment). In all cases, quantitative data were compiled from all ex-
periments. Unless otherwise noted, data are presented as the means ±
SEM. Statistical analysis was performed using GraphPad Prism 5.0
software (GraphPad Software, San Diego, CA) using analysis of var-
iance (ANOVA) with Dunnett posttests (for comparison to basal media
control) or Tukey posttests (for comparison between all media condi-
tions). Values of P≤ .05 were regarded as being statistically significant.
Results
Development of an Ex Vivo Model System for Investigating the
Influence of Organ-Specific Soluble Factors on Metastatic
Behavior of Human Breast Cancer Cells
Previous studies have uncovered several tumor cell–specific charac-
teristics that can influence organ tropism of breast cancer metastasis
[4,8–10]. However, much less is known about the organ-specific fac-
tors contributed by the secondary microenvironment itself, and this
has remained challenging to investigate. We began to address this by
establishing a comprehensive ex vivomodel system for investigating the
influence of organ-specific soluble factors on the metastatic behavior of
human breast cancer cells. Using in vivo xenograft models of metastasis
as a foundation, organs representing common sites of clinical breast
cancer metastasis were isolated from female nude mice and used to
generate CM. Organ-CM was successfully generated from lung, liver,
brain, and LNSCs and BMSCs. Stromal cells (LNSCs and BMSCs)
were observed to be adhesive in culture, with LNSCs demonstrating an
elongated and fibroblastic phenotype (Figure W3A) and BMSCs dem-
onstrating a smaller and more mesenchymal appearance (FigureW3C).
Flow cytometric analysis demonstrated that LNSCs were largely
CD45− and glycoprotein 38-positive (gp38+); with 69.2 ± 8.5% of cells
possessing a CD45− gp38+ phenotype indicative of LNSCs [24]
(Figure W3B). The BMSCs were observed to be positive for CD44
and CD29, weakly positive for CD105 and stem cell antigen-1 (Sca-1),
and negative for CD79 (Figure W3, D–H ), in close agreement with
previous studies [25,26].
Human Breast Cancer Cells Demonstrate Cell Line–Specific
Chemotactic and Proliferative Behavior in Response
to Organ-CM
We used our newly developed ex vivo model system to investigate
organ-specific metastatic cell behaviors of human breast cancer cells in
response to soluble factors present in organ-CM. The breast cancer cell
lines used in this study have been previously classified as being either
an estrogen receptor (ER−)/progesterone receptor (PR−)/human epi-
dermal growth factor receptor-positive (HER2+) subtype (SUM159
and SUM149) [19] or a triple-negative ER−/PR−/HER2− subtype
(MDA-MB-231 and MDA-MB468) [18,20]. We employed transwell
migration assays as a surrogate for metastatic dissemination (“getting
there”) and BrdU proliferation assays as a surrogate for metastatic
growth (“growing there”). Analysis of MDA-MB-231, SUM159,
SUM149, and MDA-MB-468 cell lines indicated that human breast
cancer cells demonstrate cell line–specific chemotactic behavior in
response to different organ-CM conditions (Figure 1). The MDA-MB-
231 cell line, arguably the most metastatic cell line of our panel in vivo
(Table 1), displayed increased migration toward bone-, LN-, and lung-
CM relative to basal media (P < .05) (Figure 1A). The second most
metastatic cell line in vivo, SUM159 (Table 1), demonstrated enhanced
migration to bone-, brain-, LN-, and lung-CM relative to basal media
(P < .05) (Figure 1B). SUM149 cells demonstrate less metastasis in vivo
than SUM159 cells (Table 1) and were only observed to have an
increase in migration toward lung-CM when compared to basal media
(P < .05) (Figure 1C). MDA-MB-468 cells, the least metastatic in vivo
of the four lines tested (Table 1), similarly only demonstrated increased
migration to lung-CM compared to basal media (P < .05) (Figure 1D).
Analysis of cell proliferation using BrdU assays also demonstrated
cell line–specific patterns in response to organ-CM (Figure 2), although
with more variability than migration studies. MDA-MB-231 cells
demonstrated increased proliferation in response to liver- and lung-
CM (P < .05) (Figure 2A), whereas MDA-MB-468 cells demonstrated
enhanced proliferation toward lung-CM relative to basal media (P <
.05) (Figure 2D). Although SUM159 (Figure 2B) and SUM149
(Figure 2C) cell lines appeared to have differential patterns of response
to various organ conditions, no statistically significant differences were
observed. Taken together, MDA-MB-231, SUM159, SUM149, and
MDA-MB-468 cells displayed cell line-specific and organ-specific
patterns of migration and proliferation that corresponded to their
in vivo metastatic behavior (Table 1).
Lung-CM Contains Potential Mediators of
Metastatic Behavior
We next wanted to identify soluble factors that may be influencing
the observed organ-specific chemotactic and proliferative behavior of
breast cancer cells. Lung is one of the most common sites of breast
cancer metastasis and is a significant cause of morbidity and mortality,
particularly in patients with aggressive basal-like and HER2+ subtypes
of breast cancer [3]. Taken together with our observations that lung-
CM consistently enhanced migration of all breast cancer cell lines
tested and also enhanced proliferation in two of four cell lines tested,
we decided to focus on investigating the composition of lung-CM.
Protein arrays were exposed to lung-CM and basal media (Fig-
ure 3). After background subtraction and removal of any overlap
present in basal media, densitometric analysis revealed that 70 proteins
were present on triplicate arrays. These proteins belong to many gen-
eral categories including chemokines, cytokines, growth factors, and
soluble extracellular matrix (ECM) components that may play a role
in metastatic behavior (Table W1). Queries using corresponding gene
symbols and Ingenuity Pathway Analysis revealed the presence of
several proteins in the functional categories of metastasis, migration,
neoplastic growth, and adhesion (Table W2). Of these, a further set
of specific proteins of interest was identified (Table 2), including
proteins related to lung metastasis mediators previously identified by
Massagué and colleagues [epiregulin (EREG), OPN, and urokinase-
type plasminogen activator (uPA)] [10,27–29] and proteins known
to interact with CD44, a marker of aggressive breast cancer cells [basic
fibroblast growth factor (bFGF), E-selectin (SELE), SELL, P-selectin
(SELP), and OPN] [13,16,28,30–33].
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Depletion of SELL or OPN from Lung-CM Reduces
Breast Cancer Cell Migration through CD44
Receptor-Ligand Interactions
On the basis of our interest on the role of both OPN [28] and “stem-
like” ALDHhiCD44+ cells [12,16,17] in breast cancer metastasis and
the observation that all four cell lines investigated express cell_surface
CD44 (Figure W4), we focused on investigating the functional con-
sequences of two of the identified lung-derived CD44 ligands, SELL
andOPN.Using an immunodepletion approach, SELL andOPNwere
successfully removed from lung-CM, down to equivalent levels of
those observed in basal media (Figure 4, A and B). Relative to non-
depleted lung-CM, depletion of SELL (ΔSELL) reduced the migration
of MDA-MB-231 breast cancer cells, whereas depletion of OPN
(ΔOPN) reduced both migration and proliferation (P < .05) (Figure 4,
C and D).
We next wanted to investigate whether the observed functional
effect of lung-derived OPN and SELL was occurring through CD44
receptor-ligand interactions with breast cancer cells. Pretreatment of
MDA-MB-231 cells with a CD44-blocking antibody before exposure
to nondepleted lung-CM resulted in decreased migration, down to the
level of migration seen in the presence of lung-CM depleted of SELL
or OPN (P < .05) (Figure 5A). In addition, blocking of CD44 func-
tion in MDA-MB-231 cells in the presence of ΔSELL- or ΔOPN-
depleted media resulted in no further reduction in migratory response,
suggesting that both SELL-mediated and OPN-mediated migrations
toward lung-CM are occurring through CD44 receptor-ligand inter-
actions (Figure 5A). In contrast, blocking of CD44 function did not
influence the growth of MDA-MB-231 cells in either nondepleted or
depleted lung-CM (Figure 5B).
To validate our ex vivo observations, we also investigated whether
CD44 receptor-ligand interactions might occur during in vivo lung
Table 1. In Vivo Organ-Specific Metastatic Dissemination Patterns of Different Human Breast
Cancer Cell Lines in Xenograft Nude Mouse Models of Metastasis.
LN* Lung† Liver‡ Bone§ Brain§
MDA-MB-231 ✓✓✓[47]¶ ✓✓✓✓[10,48]¶,# ✓✓ [47]# ✓✓✓[9,49]¶ ✓✓ [8,50]
SUM-159 ✓✓ [51]¶ ✓✓ [51]¶ ✓ [51] ✓✓¶,** ✓✓¶,**
SUM-149 ✓ [52] ✓✓ [52]¶
MDA-MB-468 ✓✓ [53] ✓✓ [48,53]¶,#
✓✓✓ to ✓✓✓✓, macroscopic metastases (grossly observable on necropsy)
✓ to ✓✓, microscopic metastases (observable by microscopy).
*Following mammary fat pad injection.
†Following mammary fat pad or tail vein injection.
‡Following mammary fat pad or mesenteric vein injection.
§Following mammary fat pad or intracardiac injection.
¶Significantly increased migration to corresponding organ-CM in this study (P < .05).
#Significantly increased BrdU incorporation in presence of corresponding organ-CM in this study
(P < .05).
**Author’s unpublished data.
Figure 1. Human breast cancer cells demonstrate cell line–specific chemotactic behavior in response to organ-CM. (A) MDA-MB-231,
(B) SUM 159, (C) SUM 149, or (D) MDA-MB-468 cells (5 × 104 per well) were plated in triplicate (n = 3) on top of gelatin-coated trans-
wells (8-μm pore size) before placement into either basal media (DMEM/F12 + MITO+) or organ-CM (bone, brain, liver, LN, or lung).
Migration was allowed to occur for more than 18 hours at 37°C (5% CO2). Transwells were then fixed with glutaraldehyde, stained with
Harris' hematoxylin, and developed with ammonium hydroxide. Five HPFs of view were captured per transwell, and migrated cells were
enumerated using ImageJ software (NIH). Data are presented as means ± SEM (N = 3; fold change from negative control of basal
media). *, significantly different from basal media (ANOVA with Dunnett posttest; P < .05).
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metastasis. Using an experimental breast cancer metastasis model, we
observed that normal mouse lung stained strongly for OPN and SELL
(Figure 5C , top right panels) but not for CD44 (Figure 5C , top left
panels). In contrast, breast cancer lung metastases stained positive
for CD44 and colocalized with OPN (and to a lesser extent SELL)
(Figure 5C , bottom panels), suggesting that CD44 receptor-ligand
interactions could also occur during in vivo lung metastasis.
Finally, we have previously shown that breast cancer cells with
a “stemlike” ALDHhiCD44+ phenotype exhibit an overall increase
in metastatic behavior in vivo, particularly to the lung [16]. To deter-
mine if this behavior may be due to CD44 ligand-receptor inter-
actions, we isolated ALDHhiCD44+ and ALDHlowCD44− subsets
from the MDA-MB-231 cell line through FACS (Figure W5) and
exposed them to different organ-CM. Similar to cell line–specific
in vivo and whole-population ex vivo observations (Figure 1 and Table 1),
ALDHhiCD44+ cells from the MDA-MB-231 cell line demonstrated
increased migration toward LN-, lung-, bone-, and brain-CM (P <
.05) (Figure 5D). These organ-specific increases in migration were not
observed for ALDHlowCD44− cells. Notably, ALDHhiCD44+ cells
showed the greatest migration toward lung-CM relative to all other
organ-CM (P < .05) (Figure 5D), and we hypothesized that this was
due to CD44 receptor-ligand interactions with lung-derived SELL
and/or OPN. Similar to whole-population observations (Figure 5A),
pretreatment of ALDHhiCD44+ cells with CD44-blocking antibody
before exposure to nondepleted lung-CM resulted in decreased migra-
tion, down to the level of migration in lung-CM depleted of SELL or
OPN (P < .05) (Figure 5E). In addition, blocking of CD44 function
in ALDHhiCD44+ cells in the presence of ΔSELL- or ΔOPN-depleted
media resulted in no further reduction in migratory response, suggesting
that both SELL-mediated and OPN-mediated migrations toward
lung-CM are occurring through CD44 receptor-ligand interactions in
ALDHhiCD44+ cells (Figure 5E ). Interestingly, when cells were pre-
treated with the ALDH inhibitor DEAB, migration of ALDHhiCD44+
cells also decreased in response to nondepleted or ΔSELL/ΔOPN-
depleted media (P < .05). Furthermore, combined blockade of both
CD44 and ALDH reduced migration of ALDHhiCD44+ cells down to
the level of ALDHlowCD44− cells (Figure 5E).
Discussion
The majority of breast cancer deaths occur as a result of metastatic
disease rather than from the effects of the primary tumor. Although
clinical studies have shown that breast cancer preferentially metastasizes
to lung, liver, bone, LN, and brain [3], it remains unclear whether
properties of cancer cells (“seeds”), properties of organ microenviron-
ments (“soil”), or a combination of both is responsible for this observed
Figure 2. Human breast cancer cells demonstrate cell line–specific proliferative behavior in response to organ-CM. (A) MDA-MB-231,
(B) SUM 159, (C) SUM 149, or (D) MDA-MB-468 cells (1.5 × 104 per well) were plated in triplicate (n = 3) in eight-well chamber slides
and allowed to adhere for 24 hours. Cells were washed with PBS and incubated for 72 hours in serum-free media. The media were
then changed to either basal media (DMEM/F12 + MITO+) or organ-CM (bone, brain, liver, LN, or lung). After 24 hours, cells were
incubated with 5 μl/ml BrdU for 30 minutes before fixation and staining for BrdU incorporation through immunofluorescence. Positive
cells were enumerated and determined as a percentage of total cells present (through nuclear staining with DAPI). Data are presented as
means ± SEM (N = 3; fold change from negative control of basal media). φ, significantly different from basal media (ANOVA with
Dunnett posttest; P < .05).
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organ tropism. Previous studies by Massagué and colleagues have iden-
tified particular genes expressed by breast cancer cells that mediate
organ-specific metastasis [4,8–10]. However, investigation of the fac-
tors contributed by specific metastatic microenvironments has received
much less attention. We believe that this is largely due to the technical
challenges of studying the organ microenvironment in vitro, juxtaposed
with the challenges of identifying and studying specific molecular
factors in detail using complex in vivo animal models of metastasis [34].
Although interactions between breast cancer cells and the bone micro-
environment have been extensively studied using two-dimensional and
Figure 3. Lung-CM contain potential mediators of metastatic behavior. Lungs were harvested from healthy female nude mice, and lung-
CM were generated and normalized as described in Materials and Methods section. RayBio Biotin Label-based Mouse Antibody Array I
membranes (RayBiotech Inc; N = 3 per media condition) were exposed to dialyzed, biotin-labeled medium samples, washed, labeled
with HRP-streptavidin, and visualized using chemiluminescence and film exposure. Representative arrays exposed to (A) basal media
(DMEM/F12 + MITO+) and (B) lung-CM are shown. Boxes outlined with dashed lines indicate internal positive controls; boxes outlined
with dotted lines indicate internal negative controls; and boxes outlined with solid bold lines highlight proteins of interest identified in
lung-CM but not in basal media following the shortest (10-second) film exposure. Further details about proteins of interest are provided
in Table 2.
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three-dimensional coculture models [35], studies investigating the
influence of other organ microenvironments have been limited and
have focused mainly on murine mammary cancer cells [36–39].
In the current study, we established a comprehensive ex vivo model
system for investigating the influence of organ-specific soluble factors
on the metastatic behavior of human breast cancer cells. This model
system facilitates investigation of individual metastatic behaviors of
human breast cancer cells in soluble organ conditions that mirror
common clinical sites of breast cancer metastasis, as well as allows
for identification of organ-derived factors that may provide a basis
for cross talk between disseminated tumor cells and their metastatic
microenvironments. Our results indicate that human breast cancer
cells with varying genetic backgrounds exhibit cell line–specific and
organ-specific migration and growth patterns in different organ-CM.
Importantly, these patterns reflect the known metastatic dissemination
patterns of these cell lines in vivo, thus providing validation for our
newly developed ex vivo model system. The breast cancer cell lines
used in this study have been previously classified as being either an
ER−/PR−/HER2+ subtype (SUM159 and SUM149) [19] or a triple-
negative ER−/PR−/HER2− subtype (MDA-MB-231 and MDA-MB-
468) [18,20]. Patients with breast cancer with these aggressive
molecular subtypes tend to display a high propensity for lung metastasis
that results in significant morbidity and mortality [3]. Notably, these
clinical data support the results derived from our ex vivo model system
because exposure to lung-CM increased migration of all breast cancer
cell lines tested and increased proliferation in two of four cell lines.
In addition to the usefulness of our ex vivo model system for func-
tional studies of organ tropism, the findings presented here also high-
light the lung as an important source of soluble factors that can mediate
metastasis, migration, neoplastic growth, and adhesion. Ingenuity
Pathway Analysis identified recurring molecules across these categories
including bFGF, EREG, selectins, OPN, uPA, vascular cell adhesion
molecule 1 (VCAM-1), and vascular endothelial growth factor A
(VEGFA). Due to its heparin-binding ability, bFGF can become con-
centrated in CD44-associated proteoglycans, and bursts of bFGF can
be released on ECM remodeling, causing angiogenesis and an op-
portunity for tumor cells to enter the vasculature [33]. The SELE,
SELP, and SELL are adhesion molecules found in both surface-bound
and soluble forms from different cell types (endothelial, platelet, and
leukocytes, respectively), and all three selectins act as CD44 ligands
[30–32]. SELE has been implicated in the successful transendothelial
migration of tumor cells [30], whereas SELLs and SELPs have been
associated with formation of permissive metastatic microenvironments
in lung [32]. VCAM-1 is an adhesion molecule that exists in both
soluble and surface-bound forms, and high plasma levels of VCAM-1
are associated with clinical breast cancer progression to lung [40].
VEGFA is a soluble growth factor and a key regulator of angiogenesis
that has also been shown to exert a chemoattractive effect on many
types of cancer cells including breast cancer cells [41].
Importantly, our protein array studies also revealed some com-
plementary lung-derived factors that correspond to tumor cell-derived
factors identified by Massagué’s group as being mediators of lung
metastasis, including EREG, OPN, and uPA [10]. EREG is a member
of the EGF family of growth factors and has been shown to exert
mitogenic effects in addition to being a key component of vascular
remodeling in metastasis [29]. OPN is a secreted phosphoprotein that
acts as both a chemoattractant and a matrix protein and has been im-
plicated in promotion of breast cancer cell adhesion, migration, inva-
sion, and metastasis through interactions with integrins and CD44
[28]. Finally, uPA is a secreted serine protease that interacts with cyclo-
oxygenase 2 (COX-2) (a tumor-derived factor identified by Massagué
and colleagues) to mediate breast cancer motility and invasion [27].
We were particularly intrigued by the observation that several of
the factors identified in lung-CM were CD44 ligands because CD44
has a well-established role in metastasis [33]. We thus decided to
investigate CD44 ligand-receptor interactions as an underlying mecha-
nism of the observed breast cancer cell migratory and proliferative
responses to lung-CM, using OPN and SELL as proof-of-principle
ligands. We observed that immunodepletion of SELL from lung-CM
resulted in decreased migration of MDA-MB-231 cells, whereas deple-
tion of OPN decreased both migration and proliferation. Although the
migration effects could be abrogated by pretreatment with a CD44
Table 2. Metastasis-Associated Proteins of Interest Identified by Protein Array Analysis of Lung-Conditioned Media*.
Array Position (Figure 3) Protein Name Function/Association with Metastasis References
39 bFGF, FGF2 •Binds to CD44-bound proteoglycans for localized concentration and presentation to neighboring cells [33]
• Mediates breast cancer migration, invasion, and metastasis
115 EREG • Member of epidermal growth factor family of growth factors [10,29]
• Identified by Massagué and colleagues as a mediator of lung metastasis in breast cancer
• Mediator of pulmonary extravasation
117 SELE • CD44 ligand [30]
• Adhesion molecule (soluble and surface-bound forms)
• Involved in transendothelial migration of tumor cells
303 SELL • CD44 ligand [31,32]
• Adhesion molecule (soluble and surface-bound forms)
• Associated with the formation of a permissive metastatic microenvironment in the lung
333 OPN • CD44 ligand [10,28]
• Identified by Massagué and colleagues as a mediator of lung metastasis in breast cancer
• Secreted and intracellular forms, well-established role in breast cancer cell migration and metastasis
346 SELP • CD44 ligand [31,32]
• Adhesion molecule (soluble and surface-bound forms)
• Associated with the formation of a permissive metastatic microenvironment in the lung
429 uPA • Protease, interacts with COX-2 to mediate breast cancer motility/invasion [10,27]
• COX-2 identified as a lung metastasis mediator by Massagué and colleagues
430 VCAM1 • Adhesion molecule (soluble and surface-bound forms) [40]
• Increased plasma levels of VCAM-1 associated with metastatic breast cancer
432 VEGFA • Growth factor, important in angiogenesis, therapeutic target for breast cancer [41]
*Data are derived from analysis of three separate protein arrays (N = 3) of lung-CM versus basal media.
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antibody, blocking CD44 function did not influence breast cancer cell
proliferation. This indicates that, although migration in response to
soluble lung-derived factors can be mediated by CD44 ligand-receptor
interactions, proliferative responses may be occurring through CD44-
independent mechanisms such as OPN-integrin interactions [28] or
additional mitogenic mechanisms that remain to be uncovered.
It is worthwhile noting that, although all four cell lines tested (MDA-
MB-231, SUM159, SUM-149, and MDA-MB-468) were observed to
express consistently high levels of the standard form of CD44 that
can interact with soluble lung-derived ligands to promote a significant
chemotactic response to lung-CM, we observed some cell line–specific
differences with regards to the degree of chemotactic response. Although
the underlying molecular mechanisms of this are unclear at this time,
there are several possibilities that might help to explain these differences.
Although we only examined expression of the standard form of CD44,
there are a number of different CD44 isoforms (both metastasis pro-
moting and metastasis inhibiting) [42] that may be playing a role in
the observed cell line–specific responses to lung-CM, and the differential
expression patterns of these in the different breast cancer cell lines will be
examined in future studies. Interestingly, the two cell lines that showed
the greatest chemotactic responses toward lung-CM (SUM149 and
MDA-MB-468) also express very high levels of the epidermal growth
factor receptor [19,43], which has been shown to cross-talk with OPN/
integrin and OPN/CD44 pathways at the molecular level to promote
migratory andmetastatic behavior [28]. TheMDA-MB-468 cell line also
expresses higher endogenous levels of OPN than the MDA-MB-231 cell
line [44] that may be influencing the chemotactic response to lung-CM
in an autocrine fashion, although the relative contributions and roles of
Figure 4. Depletion of SELL and OPN from lung-CM reduces breast cancer cell migration. (A and B) Lungs were harvested from healthy
female nude mice, and lung-CM were generated, normalized, and immunodepleted of SELL (A) or OPN (B) as described in Materials
and Methods section. The resulting SELL or OPN levels were assessed by ELISA in undepleted lung-CM, lung-CM exposed to Dynabeads
Protein G only, lung-CM exposed to beads plus a nonspecific anti-mouse IgG antibody, and lung-CM depleted of SELL (A) or OPN (B) using
beads plus specific anti-mouse antibodies (“ΔSELL” or “ΔOPN”). (A and B) Data are presented as means ± SEM (N = 3). (C) MDA-MB-231
human breast cancer cells (5 × 104 per well) were plated in triplicate (n = 3) on top of gelatin-coated transwells (8-μm pore size) before
placement into basal media (DMEM/F12 + MITO+), undepleted lung-CM, or lung-CM depleted of SELL or OPN. Migration was allowed to
occur for more than 18 hours at 37°C (5% CO2). Transwells were then fixed with glutaraldehyde, stained with Harris' hematoxylin, and
developed with ammonium hydroxide. Five HPFs of view were captured per transwell, and migrated cells were enumerated using ImageJ
software (NIH). (D) MDA-MB-231 cells (1.5 × 104 per well) were plated in triplicate (n= 3) in eight-well chamber slides and allowed to adhere
for 24 hours. Cells were washed with PBS and then incubated for 72 hours in serum-free media. The media were then changed to basal
media (DMEM/F12 +MITO+), undepleted lung-CM, or lung-CM depleted of SELL or OPN. After 24 hours, cells were incubated with 5 μl/ml
BrdU for 30 minutes before fixation and staining for BrdU incorporation through immunofluorescence. Positive cells were enumerated
and determined as a percentage of total cells present (through nuclear staining with DAPI). (C and D) Data are presented as means ±
SEM (N = 3; fold change from negative control of basal media). *, significantly different from basal media; δ, significantly different from
undepleted lung-CM (ANOVA with Tukey posttest; P < .05).
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Figure 5. Soluble lung-derived factors mediate breast cancer cell migration through CD44 receptor-ligand interactions. (A and B) To assess
the combined role of CD44 in SELL- and OPN-mediated breast cancer migration and growth, MDA-MB-231 cells were preincubated at RT
for 30minutes in the presence (ΔCD44) or absence of 10 μg/ml rat anti-human CD44 antibody before being subjected to transwell migration
(A) or BrdU incorporation (B) assays using lung-CM as described for Figure 4. (C) MDA-MB-231 human breast cancer cells were injected
into the tail vein of female nude mice using an established model of experimental metastasis (1 × 106 cells per mouse; n = 5 mice). At
8 weeks post-injection, mice were killed and assessed for metastatic burden in the lung using histopathology. Serial tissue sections were
subjected to immunohistochemical analysis of CD44 (red staining; AP-Red), SELL (brown staining; DAB), and/or OPN (brown staining; DAB)
in normal lung tissue (top panels) and lung metastases (bottom panels). Representative sections are shown; all scale bars, 100 μm. (D and
E) ALDHhiCD44+ (black bars) or ALDHlowCD44− (gray bars) cell populations were isolated from the MDA-MB-231 human breast cancer cell
line using FACS as described in Figure W3 and subjected to transwell migration assays using organ-CM (bone, brain, liver, LN, and lung) as
described for Figure 1 (D) or preincubated at RT for 30 minutes in the presence (ΔCD44) or absence of 10 μg/ml rat anti-human CD44
antibody and/or 100 μM of the ALDH inhibitor DEAB (100 μM) before being subjected to transwell migration assays using lung-CM as
described for Figure 4 (E). All graphical data are presented as means ± SEM (N = 3; fold change from negative control of basal media).
*, significantly different from basal media; δ, significantly different from undepleted lung-CM; φ, significantly different from untreated
MDA-MB-231 cells in the same respective lung-CM conditions (ANOVA with Tukey posttest; P < .05).
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tumor-derived versus microenvironment-derived OPN remain poorly
understood [28]. Ongoing studies are aimed at further delineating the
differential tumor-derived molecular factors that can interact with lung-
derived soluble factors to mediate breast cancer migration and growth.
In addition to the role of CD44 in metastasis, recent studies have also
highlighted its role in normal stem cell mobilization and homing as well
as establishment of the premetastatic niche [45]. CD44 receptor-ligand
interactions may be especially important in the context of “stemlike”
tumor cells in metastasis, as one of the key putative characteristics
of breast cancer tumor–initiating cells is that of CD44 positivity
[13]. Indeed, we observed that isolated breast cancer cells with an
ALDHhiCD44+ phenotype responded in an organ-specific chemotactic
manner, whereas ALDHlowCD44− cells did not. This suggests that
ALDHhiCD44+ breast cancer cells may be driving the organotropic
behavior of whole cell populations. Furthermore, our previous observa-
tion that ALDHhiCD44+ breast cancer cells exhibit an overall increase
in metastatic behavior in vivo with a particular propensity for the lung
[16] is supported by the findings of the current study, where we observed
that ALDHhiCD44+ cells displayed preferential migration toward lung-
CM relative to all other organs. Similar to our results in whole breast can-
cer cell populations, we observed that migration of ALDHhiCD44+ cells
could be mediated by CD44 receptor-ligand interactions. However, we
further observed that pretreatment with the ALDH inhibitor
DEAB also decreased migration of ALDHhiCD44+ cells in response to
nondepleted or ΔSELL/ΔOPN-depleted lung-CM, and that com-
bined blockade of both CD44 and ALDH reduced migration of
ALDHhiCD44+ cells down to the level of ALDHlowCD44− cells. This
suggests an additive role for both CD44 and ALDH pathways in medi-
ating migration toward soluble lung-derived factors. This was some-
what unexpected, as previous studies have mainly implicated ALDH in
retinoic acid synthesis, cellular self-protection, differentiation, and/or
proliferation, rather than in processes such as migration [46]. Further-
more, the ALDH-mediated migration effect was only observed in lung-
CM but not in basal media, supporting the idea that interactions with
soluble lung-derived factors may be influencing this behavior. To the
best of our knowledge, none of the 70 proteins identified in lung-CM
have previously been shown to interact with ALDH; however, this is
currently under further investigation.
In summary, this study reports the establishment and validation of
a comprehensive ex vivo model system for investigating the influence
of organ-specific soluble factors on metastatic behavior of human breast
cancer cells. Our results indicate that multiple human breast cancer cells
exhibit organ-specific and cell line–specific migration and growth pat-
terns toward specific organ conditions in a manner that reflects their
metastatic behavior in vivo. Our results also highlight the lung as an
important source of soluble factors that mediate metastatic behavior
and suggest for the first time that interactions between subpopulations
of CD44-expressing breast cancer cells (including ALDHhiCD44+ cells)
and soluble factors present in the lung microenvironment may play an
important role in determining organotropic metastatic behavior. These
findings lay the groundwork for a number of future studies, including
investigation of the role of other soluble CD44 ligands in lung metas-
tasis, the complementary involvement of lung-derived insoluble/ECM
factors in mediating breast cancer cell behavior (particularly colonization
and proliferation), and molecular interrogation of CM derived from
other organs. Taken together, further elucidation of the cross talk
between “seed” and “soil” during organ-specific metastasis and the trans-
lation of this knowledge into the clinic will have important implications
for the management and treatment of breast cancer.
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Supplemental Materials and Methods
Flow Cytometry Characterization of Primary Cell Isolates
and Human Breast Cancer Cells
Isolated LNSC and BMSC populations were characterized by flow
cytometry on the basis of previous studies [1,2] (Figure W1). LNSCs
(1 × 105) were incubated with FITC-conjugated anti-CD45 and
phycoerythrin (PE)–conjugated anti-gp38 antibodies (eBioscience,
San Diego, CA), followed by incubation with 7-aminoactinomycin
D (7-AAD; BD Biosciences). BMSCs (1 × 105) were labeled with
anti–Sca-1, anti-CD105, anti-CD73, anti-CD29, or anti-CD44 anti-
bodies (R&D Systems Inc, Minneapolis, MN). All samples were then
labeled with a goat anti-rat PE-conjugated secondary antibody (R&D
Systems), followed by incubation with 7-AAD.
Human breast cancer cell lines (MDA-MB-231, SUM159, SUM149,
and MDA-MB-468; 1 × 105 cells) were characterized for CD44 expres-
sion by flow cytometry using a PE-conjugated anti-CD44 antibody
(clone IM7; BD Biosciences) (Figure W2).
For all flow cytometry experiments, appropriate IgG isotype controls
were used to assess nonspecific staining. Cells (1 × 105 viable events)
were analyzed using an EPICS XL-MCL flow cytometer (Beckman
Coulter, Fullerton, CA). Methodology for the FACS analysis (Fig-
ure W3) is provided in the main body of the manuscript.
Fluorescence-Activated Cell Sorting
Cell subpopulations (ALDHhiCD44+CD24− and ALDHlow-
CD44low/−CD24+) were isolated from the MDA-MB-231 cell line
as described previously [3,4]. Briefly, cells were concurrently labeled
with 7-AAD, ALDEFLUOR assay kit (STEMCELL Technologies,
Vancouver, British Columbia) and fluorescently conjugated anti-
bodies including anti-CD44 (clone IM7) conjugated to allophyco-
cyanin and anti-CD24 (clone ML5) conjugated to PE (BD Biosciences).
ALDH activity was used as the primary sort criteria (top ∼20% =
ALDHhi; bottom ∼20% = ALDHlow) and CD44+CD24– phenotype
as the secondary sort criteria (top ∼10% gated on ALDHhi; bottom
∼10% gated on ALDHlow). Cell viability was assessed by 7-AAD
staining during cell sorting and confirmed by trypan blue exclusion
postsorting. FACS-isolated cells were used immediately for in vitro
migration assays.
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Figure W1. Migration of MDA-MB-231 cells in response to increasing concentrations of organ-CM. Cells (5 × 104 per well) were plated in
triplicate (n = 3) on top of gelatin-coated transwells (8-μm pore size) before placement into either basal media (DMEM/F12 + MITO+) or
increasing concentrations (0.0156, 0.0312, 0.0468, and 0.0624 g of tissue per milliliter) of organ-CM: (A) bone, (B) brain, (C) liver, (D) LN, or
(E) lung. Migration was allowed to occur for more than 18 hours at 37°C (5% CO2). Transwells were then fixed with glutaraldehyde, stained
with Harris' hematoxylin, and developed with ammonium hydroxide. Five HPFs of viewwere captured per transwell, andmigrated cells were
enumerated using ImageJ software (NIH). Data are presented as means ± SEM (N = 3; fold change from negative control of basal media).
No significant differences between CM concentrations were noted. Therefore, we carried out the remainder of our migration experiments
with the lowest dose, 0.0156 g/ml, which allowed us to see physiologically relevant differences in migration and still use the media in a
conservative fashion, thus reducing the number of mice needed to generate enough media for all experiments.
Figure W2. Proliferation of MDA-MB-231 cells in response to increasing concentrations of organ-CM. Cells (1.5 × 104 per well) were plated
in triplicate (n= 3) in eight-well chamber slides and allowed to adhere for 24 hours. Cells were washed with PBS and incubated for 72 hours
in serum-free media. The media were then changed to either basal media (DMEM/F12 + MITO+) or increasing concentrations (0.0156,
0.0312, 0.0468, and 0.0624 g of tissue per milliliter) of organ-CM: (A) bone, (B) brain, (C) liver, (D) LN, or (E) lung. After 24 hours, cells
were incubated with 5 μl/ml BrdU for 30 minutes before fixation and staining for BrdU incorporation through immunofluorescence. Positive
cells were enumerated and determined as a percentage of total cells present (through nuclear staining with DAPI). Data are presented as
means± SEM (N =3; fold change from negative control of basal media). *, significantly different from basal media; φ, significantly different
from lowest respective organ-CM concentration (0.0156 g of tissue per milliliter of media) (ANOVAwith Dunnett posttest; P< .05). Because
the highest concentration of organ-CM (0.0624 g of tissue per milliliter of media) gave the most consistent proliferative response across
organs, we therefore carried out the remainder of our proliferation assays using this concentration.
Figure W3. Characterization of LNSCs and BMSCs. (A) Bright-field microscopy image showing the morphology of LNSCs. (B) Repre-
sentative flow cytometry analysis of LNSCs using a PE-conjugated gp38 antibody and a FITC-conjugated CD45 antibody. (C) Bright-field
microscopy image showing themorphology of BMSCs. (D–H) Representative flow cytometry analysis of BMSCs using PE-conjugated (black
profiles) antibodies against (D) CD44, (E) CD106, (F) Sca-1, (G) CD29, and (H) CD73 antibodies relative to the isotype control (white profiles).
A minimum of 10,000 viable events were collected per sample.
Figure W4. Human breast cancer cell lines express CD44. (A–D) Flow cytometry analysis of CD44 in (A) MDA-MB-231, (B) SUM 159,
(C) SUM 149, or (D) MDA-MB-468 human breast cancer cells. Cells (1 × 105) were labeled with an anti-CD44 antibody (clone IM7)
conjugated to PE or an IgG-PE isotype control. Representative histograms of CD44 expression (black profiles) relative to the IgG isotype
control (white profiles) are shown. A minimum of 10,000 viable events were collected per sample.
Figure W5. Strategy for FACS isolation of ALDHhiCD44+ and ALDHlowCD44− cells. MDA-MB-231 cells were concurrently labeled with
7-AAD, CD44-allophycocyanin, CD24-PE, and theALDEFLUOR assay kit. Cell subsetswere isolated using a four-color protocol on a FACSAria
III (Becton Dickinson). (A) Cells were selected on the basis of expected light scatter, (B) then for singlets, and (C) viability based on 7-AAD
exclusion. (D) Cells were analyzed for ALDH activity, and the top 20% most positive were selected as the ALDHhi population, whereas the
bottom 20% of cells with the lowest ALDH activity were deemed to be ALDHlow. (E) Finally, 50% of the ALDHlow cells were further selected
on the basis of a CD44low/−CD24+ phenotype, and (F) 50% of the ALDHhi cells were selected on the basis of CD44+CD24− phenotype. The
isolated cells were used for the functional analyses of migration and growth in the presence of organ-CM in vitro (Figure 5, D and E ).
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